Pharmaceutical

Alvotech and Bioventure gain approval for Humira biosimilar in Egypt

Alvotech and Bioventure received the Egyptian Drug Authority's approval to produce and supply AVT02 (adalimumab), a biosimilar for Humira.

Aug 30, 2023 - 20:00
Alvotech and Bioventure gain approval for Humira biosimilar in Egypt
Alvotech and Bioventure received the Egyptian Drug Authority's approval to produce and supply AVT02 (adalimumab), a biosimilar for Humira.
Read the original article

Tags:

Previous Article

EC grants approval to Merck’s Keytruda for gastric cancer

Next Article

Ipilimumab by Bristol-Myers Squibb for Metastatic Transitional (Urothelial) Trac...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novel drug approvals declined in 2022 but what are the CMO opportunities in 2023?

Novel drug approvals declined in 2022 but what are the ...

Mar 27, 2023

STAT+: Is there $21 billion left for Covid response, or $5 billion? The White House is using fuzzy math

STAT+: Is there $21 billion left for Covid response, or...

Mar 30, 2023

STAT+: ‘It’s like Groundhog Day’: The cancer drug shortage isn’t new — and neither are the solutions

STAT+: ‘It’s like Groundhog Day’: The cancer drug short...

Jun 28, 2023